Entera Bio Ltd. (ENTX) stock
ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.11−0.11 (-3.42%)
Close on Nov 13, 2026Market cap $538.47MP/E –Yield –
Entera Bio gross margin
Gross margin is gross profit as a percentage of revenue.
Entera Bio's gross margin for the twelve months ending Dec 31, 2025 was 0.0%. For fiscal 2025 it was 0.0%, against 5.0% the year before. The highest annual figure on record is 34.7% in fiscal 2021.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0.0% | −5.0 |
| FY2024 | Dec 31, 2024 | 5.0% | −19.7 |
| FY2022 | Dec 31, 2022 | 24.6% | −10.0 |
| FY2021 | Dec 31, 2021 | 34.7% | +16.9 |
| FY2020 | Dec 31, 2020 | 17.8% | +6.8 |
| FY2019 | Dec 31, 2019 | 11.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | 0.0% | −42.9 |
| Q4 FY2024 | Dec 31, 2024 | 0.0% | −25.0 |
| Q3 FY2024 | Sep 30, 2024 | 0.0% | −25.0 |
| Q2 FY2024 | Jun 30, 2024 | 15.8% | −4.8 |
| Q4 FY2022 | Dec 31, 2022 | 42.9% | +25.3 |
| Q3 FY2022 | Sep 30, 2022 | 25.0% | −28.6 |
| Q2 FY2022 | Jun 30, 2022 | 25.0% | +15.8 |
| Q1 FY2022 | Mar 31, 2022 | 20.6% | −32.9 |
| Q4 FY2021 | Dec 31, 2021 | 17.6% | −22.8 |
| Q3 FY2021 | Sep 30, 2021 | 53.6% | +37.4 |
| Q2 FY2021 | Jun 30, 2021 | 9.2% | – |
| Q1 FY2021 | Mar 31, 2021 | 53.5% | – |
| Q2 FY2020 | Jun 30, 2020 | 40.4% | – |
| Q2 FY2019 | Jun 30, 2019 | 16.2% | – |
See a number that looks wrong?